Point-of-Care PGx Test Enables Rapid Appropriate Antiplatelet Prescription for Stroke Patients

CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. Pharmacogenetic testing assists prescribers in selecting tailored treatment and doses that are most effective and avoid those that may cause adverse reactions in an individual with a known genetic variant. This facilitates effective prescription in a clinically relevant timeframe, thereby improving patient outcomes. Now, a rapid point of care (POC) test for CYP2C19 genotyping can effectively guide antiplatelet therapeutics in time-critical settings.

The Genedrive CYP2C19 ID Kit from genedrive plc (Manchester, UK) provides rapid, automated results of CYP2C19 genotypes to inform clinicians on an individual’s metabolizer status according to CPIC guidelines in treatment strategies using therapeutics that are metabolized by CYP2C19. The Genedrive CYP2C19 ID Kit is the only POC genetic test to aid clinicians’ therapeutic treatment decisions for drugs that are metabolized by CYP2C19, and that are specifically affected by DNA variant alleles 2, 3, 4, 8, 17, and 35.

The test provides rapid, actionable results in approximately 69 minutes, including diplotype and CPIC-coded metabolizer status, enabling personalized treatment for antiplatelet therapies. The non-invasive test uses a single buccal swab and has a simple-to-follow workflow. The Genedrive CYP2C19 ID Kit is used in conjunction with the Genedrive System, featuring a compact benchtop design that allows it to be placed at the POC. Designed to be used in time-critical situations, before treatment prescription, it uses gene detection technology​ to provide automated and easy-to-interpret actionable results.

Related Links:
genedrive plc